These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31597277)

  • 1. Innovations in Pediatric Drug Formulations and Administration Technologies for Low Resource Settings.
    Gerrard SE; Walsh J; Bowers N; Salunke S; Hershenson S
    Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31597277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric drug formulations: a review of challenges and progress.
    Ivanovska V; Rademaker CM; van Dijk L; Mantel-Teeuwisse AK
    Pediatrics; 2014 Aug; 134(2):361-72. PubMed ID: 25022739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric prescribing in tertiary care teaching hospital of Delhi (India): fragmenting medicines for use.
    Tayal H; Roy V; Singhal S; Dubey AP
    Eur J Pediatr; 2020 Sep; 179(9):1435-1443. PubMed ID: 32185474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
    Giacoia GP; Taylor-Zapata P; Zajicek A
    Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are age-appropriate antibiotic formulations missing from the WHO list of essential medicines for children? A comparison study.
    Ivanovska V; Leufkens HG; Rademaker CM; Zisovska E; Pijnenburg MW; van Dijk L; Mantel-Teeuwisse AK
    Arch Dis Child; 2017 Apr; 102(4):352-356. PubMed ID: 28119403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA.
    Bajcetic M; Kearns GL; Jovanovic I; Brajovic M; van den Anker JN
    Curr Pharm Des; 2015; 21(39):5668-73. PubMed ID: 26323413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Providing Suitable Pediatric Formulations for Canadian Children: A Call for Action.
    Litalien C; Autmizguine J; Carli A; Giroux D; Lebel D; Leclerc JM; Théorêt Y; Gilpin A; Bérubé S
    Can J Hosp Pharm; 2020; 73(4):247-256. PubMed ID: 33100356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European perspectives on pediatric formulations.
    Breitkreutz J
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatric Formulation Initiative: selected reports from working groups.
    Giacoia GP; Taylor-Zapata P; Mattison D
    Clin Ther; 2008 Nov; 30(11):2097-101. PubMed ID: 19108797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Explaining the slow transition of child-appropriate dosage formulations from the global to national level in the context of Uganda: a qualitative study.
    Nsabagasani X; Hansen E; Mbonye A; Ssengooba F; Muyinda H; Mugisha J; Ogwal-Okeng J
    J Pharm Policy Pract; 2015; 8(1):19. PubMed ID: 26203358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation science in resource-poor countries and communities.
    Yapa HM; Bärnighausen T
    Implement Sci; 2018 Dec; 13(1):154. PubMed ID: 30587195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 10 years EU regulation of pediatric medicines - impact on cardiovascular drug formulations.
    Thabet Y; Slavkova M; Breitkreutz J
    Expert Opin Drug Deliv; 2018 Mar; 15(3):261-270. PubMed ID: 29284286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities for enteral drug delivery for neonates, infants, and toddlers: a critical exploration.
    Kaneria NS; Tuleu C; Ernest T
    Expert Opin Drug Deliv; 2022 May; 19(5):475-519. PubMed ID: 35404191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Focus Group Study about Oral Drug Administration Practices at Hospital Wards-Aspects to Consider in Drug Development of Age-Appropriate Formulations for Children.
    Rautamo M; Kvarnström K; Sivén M; Airaksinen M; Lahdenne P; Sandler N
    Pharmaceutics; 2020 Jan; 12(2):. PubMed ID: 32019100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building reliable supply chains for noncommunicable disease commodities: lessons learned from HIV and evidence needs.
    Pastakia SD; Tran DN; Manji I; Wells C; Kinderknecht K; Ferris R
    AIDS; 2018 Jul; 32 Suppl 1():S55-S61. PubMed ID: 29952791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric therapeutics and medicine administration in resource-poor settings: a review of barriers and an agenda for interdisciplinary approaches to improving outcomes.
    Craig SR; Adams LV; Spielberg SP; Campbell B
    Soc Sci Med; 2009 Dec; 69(11):1681-90. PubMed ID: 19796859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovations and adaptations in neonatal and pediatric respiratory care for resource constrained settings.
    Wu A; Mukhtar-Yola M; Luch S; John S; Adhikari BR; Bakker C; Slusher T; Bjorklund A; Winter J; Ezeaka C
    Front Pediatr; 2022; 10():954975. PubMed ID: 36389382
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.